The FDA has approved Vosevi (sofosbuvir-velpatasvir-voxilaprevir, Gilead Sciences), a single-tablet pangenotypic regimen, for the second-line treatment for chronic hepatitis C virus infection in adults without cirrhosis or with mild cirrhosis.
Vosevi is the first once-daily single-tablet HCV regimen to be approved for patients who have been treated unsuccessfully with direct-acting antiviral drugs, according to a company press release. The tablet contains two previously approved DAAs,